# Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy

Source: https://onco.cc/trials/nct06998108/  
OnCo record `nct06998108` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing BEBT-209 in HR-positive / HER2-negative breast cancer, now recruiting.

## Summary

Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy is a phase 3 interventional study registered as NCT06998108, led by BeBetter Med with Chinese Academy of Medical Sciences, and recruiting on the registry. Official title: A Multicenter, Randomised, Controlled, Double-blind Phase III Clinical Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant for the Treatment of HR+/HER2- Locally Advanced or Metastatic Breast Cancer in Patients With Disease Progression After Prior Endocrine Therapy. Planned enrolment is 330 participants (estimated). The study started in 2022-06-09 and primary completion is expected in 2025-12-31. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06998108
- Phase: 3
- Setting: A Multicenter, Randomized, Controlled, Double-blind Phase III Clinical Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant for the Treatment of HR+/HER2- Locally Advanced or Metastatic Breast Cancer in Patients With Disease Progression After Prior Endocrine Therapy
- Sponsor: BeBetter Med
- Enrolled: 330

## Sources

- ClinicalTrials.gov NCT06998108: https://clinicaltrials.gov/study/NCT06998108

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- drugs: [BEBT-209](https://onco.cc/drugs/bebt-209/)
- companies: [BeBetter Med](https://onco.cc/companies/bebetter-med/)

---
JSON: https://onco.cc/api/v1/entities/nct06998108.json